Fed Circuit rules against Mylan in patent dispute over epilepsy drug

04-02-2019

Fed Circuit rules against Mylan in patent dispute over epilepsy drug

sudok1 / iStockphoto.com

Generic-drug manufacturers Mylan Pharmaceuticals, Breckenridge Pharmaceutical and Alembin Pharmaceuticals have lost their bid to prove that claims in a patent owned by US company Research Corporation Technologies, were invalid on the grounds of obviousness.


Mylan Pharmaceuticals, Research Corporation Technologies, US Court of Appeals for the Federal Circuit, patent validity, US Patent Trial and Appeal Board

More on this story

PTAB upholds anti-epileptic drug patent
27-03-2017

LSIPR